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ABSTRACT
Histone post-translational modifications are key con-
tributors to chromatin structure and function, and
participate in the maintenance of genome stability.
Understanding the establishment and maintenance
of these marks, along with their misregulation in
pathologies is thus a major focus in the field. While
we have learned a great deal about the enzymes reg-
ulating histone modifications on nucleosomal his-
tones, much less is known about the mechanisms
establishing modifications on soluble newly synthe-
sized histones. This includes methylation of lysine
9 on histone H3 (H3K9), a mark that primes the for-
mation of heterochromatin, a critical chromatin land-
mark for genome stability. Here, we report that H3K9
mono- and dimethylation is imposed during trans-
lation by the methyltransferase SetDB1. We discuss
the importance of these results in the context of het-
erochromatin establishment and maintenance and
new therapeutic opportunities in pathologies where
heterochromatin is perturbed.
INTRODUCTION
Prior to their incorporation into chromatin, newly synthe-
sized histones proceed through a maturation cascade of
several biochemical complexes (1,2). This cascade, medi-
ated by the association with various histone chaperones
(3), ensures proper folding and the establishment of post-
translational modifications (4). Our previous work, along
with others, isolated distinct biochemical complexes, iden-
tifying key players that participate in histone maturation
(1,2). In the earliest isolated complex, histones H3 and H4
associate with the heat shock proteins Hsc70 and Hsp90/70,
respectively, either during their synthesis or once translated.
Subsequently, histones H3 and H4 form a heterodimer as-
sisted by the Hsp90 protein and the histone chaperone
testicular nuclear autoantigenic sperm protein (tNASP).
The dimer then interacts with the histone chaperones anti-
silencing function 1 (ASF1) and somatic NASP (sNASP), as
well as the histone acetyltransferase 1 (HAT1), consistent
with the observation of acetylation at H4K5 and H4K12,
a prominent mark of newly synthesized histones (5,6). The
H3-H4 dimer then interacts with Importin4, which medi-
ates its translocation to the nucleus (1,2). Importantly, we
observed H3K9me1 in each complex, suggesting that this
mark is established even earlier in the maturation cascade.
H3K9me1 is a key mark in the establishment of func-
tional heterochromatin (7). Indeed, H3K9me1 is a preferred
substrate for the suppressor of variegation 3–9 (SUV39)
methyltransferase (8), which catalyzes H3K9me3, a hall-
mark of heterochromatin and gene silencing (9). Thus, the
cell must ensure that certain population of histones fea-
ture H3K9me1, priming them for further modifications
that enable heterochromatin formation. Consistent with
this, SetDB1, a methyltransferase implicated in catalyzing
H3K9me1 on soluble histones, exists in a nuclear complex
with the histone chaperone chromatin assembly factor 1
(CAF-1) and heterochromatin protein 1 alpha (HP1) (8).
This complex participates in the formation of heterochro-
matin by (i) depositing the replicative histone variant H3.1-
H4 onto newly synthesized DNA, a reaction mediated by
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CAF-1, and (ii) targeting HP1 to heterochromatin sites
(10). Thus, the SetDB1/HP1/CAF-1 complex links the
establishment of histone H3 methylation and heterochro-
matin formation. Although the SetDB1/HP1/CAF-1
complex may catalyze H3K9 methylation on soluble his-
tones in the nucleus, it does not explain why we observe
H3K9me1 in the first complex isolated in the maturation
cascade (1,2). In this work we aimed to identify when
H3K9me1 first occurs and the enzyme responsible for its
catalysis.
Here we report that H3K9 is mono- and dimethylated
while bound to the ribosome and its catalysis occurs co-
translationally. We then identified that the methyltrans-
ferase SetDB1 associates with ribosomes and catalyzes
H3K9me1 and H3K9me2 during translation. Our data en-
able us to refine our current model, where SetDB1 exists
in two distinct complexes, each responsible for catalyzing
H3K9me1 at different stages in histone metabolism. We dis-
cuss how these two mechanisms cooperate to ensure that
a sufficient amount of histones feature H3K9me1 to en-
able the establishment and maintenance of functional het-
erochromatin domains. Finally, we discuss how these data
open new avenues to explore SetDB1 as a therapeutic target
in cancers having perturbed heterochromatin regions.
MATERIALS AND METHODS
Antibodies
ASF1a/b (11), CAF-1/p150 (Novus Biologicals #NB500–
207A1), DAXX (Santa Cruz #sc-7152), HAT1 (Abcam
#ab12164), HIRA (Abcam #ab20655), Histone H3 (Ab-
cam #ab7834), H3K9me1 (Millipore #07–450), H3K9me2
(Millipore, #07–212), H4K12ac (Millipore #07–595),
Hsc70 (Abcam #ab19136), Hsp90 (Santa Cruz #sc-7947),
Importin4 (Abcam #ab28387), MCM2 (BD Transduc-
tion Lab #610700), MCM5 (Bethyl A300–195A), NASP
(donated by Dr Almouzni), RPL5 (Abcam #ab74744),
RPS3a (Abcam, ab171742), SetDB1 (Abcam #ab12317).
For Western blot analysis the primary antibodies were de-
tected with a horseradish peroxidase-conjugated secondary
antibody, developed with enhanced chemiluminescence
(ECL, Pierce) and exposed onto an X-ray film.
Ribosome purification
Ribosomes were purified from HeLa cells as described (12).
In brief, HeLa cells cultured at 80% confluence were incu-
bated with 0.1 mg/ml cycloheximide during 1 h. After this,
cells were trypsinized, PBS washed and lysed with the ribo-
some lysis buffer (100 mM Tris-HCl pH 7.4, 50 mM KCl, 25
mM MgCl2, 0.1 mg/ml cycloheximide, 1 mM DTT, 1 mM
PMSF, 1% Triton X-100) during 15 min on ice, and cen-
trifuged at 13 800 g for 15 min. The supernatant was loaded
onto a 35% sucrose cushion (10 mM Tris-HCl pH 7.4, 85
mM KCl, 5 mM MgCl2, 35% sucrose) and ultracentrifuged
in the SW55 rotor (Beckman) for 16 h at 116 000 g, 4◦C.
The ribosome-containing pellet was resuspended in the ri-
bosome resuspension buffer (10 mM Tris-HCl pH 7.4, 10
mM NaCl, 3 mM MgCl2, 0.2 mM DTT).
Histone processing and mass spectrometry analysis
Histone bands were separated by SDS-PAGE, stained with
Coomassie (Brillant blue G-250) and excised at appropri-
ate height. Bands were destained in 50% acetonitrile/50%
100 mM ammonium bicarbonate. Histones were chemi-
cally modified by propionylation (30 min, room tempera-
ture, 2.5% propionic anhydride (Sigma) in ammonium bi-
carbonate at pH 7.5) to prevent tryptic cleavage. Histone
proteins were then digested with trypsin (Promega, 200 ng
in 50 mM ammonium bicarbonate) overnight and the su-
pernatant desalted by Carbon TopTips (Glygen) according
to manufacturer’s instructions. The peptides were injected
in an Ultimate 3000 HPLC system (LC Packings Dionex)
and separated with a gradient from 5% to 60% acetoni-
trile in 0.1% formic acid over 40 min at 300 nl/min on a
75 m ID X 10 cm ReproSil-Pur C1-AQ analytical column
(2.4 m; Dr. Maisch GmbH Germany). The effluent from
the HPLC was directly electro-sprayed into the LTQ Orbi-
trap XL mass spectrometer (Thermo Fisher Scientific). The
MS instrument was operated in the data-dependent mode
to automatically switch between full scan MS and MS/MS
acquisition. Survey full scan spectra (m/z 250–2000) were
acquired in the Orbitrap with resolution R = 60 000 at
m/z 400. For all measurements with the Orbitrap detector,
three lock-mass ions from ambient air (m/z = 371.10123,
445.12002, 519.13882) were used for internal calibration.
The six most intense peptide ions with charge state between
two and five were sequentially isolated (window = 2.0 m/z)
to a target value of 10 000 and fragmented in the linear
ion trap by collision-induced dissociation (CID). Fragment
ion spectra were recorded in the linear trap of the instru-
ment. A dynamic exclusion time of 180 s was applied. Typ-
ical mass spectrometric conditions were: spray voltage 1.4
kV; no sheath and auxiliary gas flow; heated capillary tem-
perature 200◦C; normalized collision energy 35% for CID
in linear ion trap. An activation q = 0.25 and activation
time of 30 ms were used. Data analysis was performed with
XCalibur Qual Browser software (Thermo Fisher Scien-
tific) by using doubly and triply charged peptide masses for
extracted ion chromatograms (XICs). XICs were checked
manually and values exported to Excel for further calcula-
tions as described before (13).
Histone peptide methyltransferase assay
Recombinant SetDB1 or ribosomes (100 ng/l RNA) were
incubated with 3 M of histone H3 peptide containing
the first 20 amino acids, either unmodified, mono-, di- or
trimethylated at K9, in the presence of 60 M S-adenosyl-
methionine (SAM) as the donor methyl group, for 240 min
(or as indicated) at 37◦C. The reaction buffer contained
25 mM Tris-HCl pH 8.5, 4 mM DTT and 5 mM MgCl2.
The reaction was stopped by adding tri-fluoroacetic acid
to a final concentration of 0.1% (v/v). Methylated pep-
tides were detected by MALDI-TOF mass spectrometry
using -cyano-4-hydroxy-cinnamic acid as the analyte ma-
trix. Its relative abundance was determined using the free-
access software mMass v5.5.0 (14), and expressed as the per-
centage of the total peptide peak areas. We used the fol-
lowing equation: (AUC H3K9me1 + AUC H3K9me2 +
AUC H3K9me3) / (AUC H3 + AUC H3K9me1 + AUC

















































































































Figure 1. Histone H3K9 mono- and dimethylation occurs at ribosomes. (A) Increasing amounts of ribosomes (0.2 and 0.6 ug of ribosomal RNA) were
analyzed by Western blot, as indicated. Input corresponded to 0.5% of the total amount of HeLa derived extract loaded onto the sucrose cushion for
the purification of ribosomes, corresponding to 15 ug of ribosomal RNA. (B) Increasing amounts of ribosomes (0.5 and 1.5 ug of ribosomal RNA) were
analyzed by agarose gel for the presence of the 28S and 18S ribosomal RNAs. (C) Isotopic distribution of the mono- and dimethylated H3 (9–17) peptides
(ion charge = 2+), from which the MS2 spectrum was acquired to locate the methyl groups on K9 (Supplementary Figure S2) (m/z = the mass-to-charge
ratio; m = the monoisotopic mass value; mass = difference between the excepted and the measured masses; R = resolution of the MS measurement).
(D) Quantification of the modifications on H3 peptides (3–8) and (18–26) from ribosomal bound histones H3. Standard deviation derived from three
independent experiments.
Figure 2. Ribosomes feature H3K9 mono- and dimethyltransferase activity. (A) Histone methyltransferase assay using an aliquot of 1 ug (RNA content)
of ribosomes (right, labeled as ‘Ribosomes’) or buffer (left, labeled as ‘No enzyme’) mixed with 60 M SAM and 5 M of histone H3 peptides from amino
acids 1–20 that were unmethylated (H3(1–20)), monomethylated on the residue K9 (H3(1–20)K9me1), dimethylated on the residue K9 (H3(1–20)K9me2),
or trimethylated on the residue K9 (H3(1–20)K9me3), for 4 h at 37◦C. The reaction was stopped with 0.1% TFA and the methylated products detected by
MALDI-TOF mass spectrometry. (B) Quantitation analysis of all the methylated peptides for each peptide substrate, expressed as percent of the total H3
peptides, as explained in Materials and Methods. Standard deviation was obtained from three independent assays.




Figure 3. Co-translational histone H3K9 methylation. (A) Scheme illustrating the procedure employed to in vitro puromycilate nascent polypeptides. (B)
Western blot analysis of the puromycilation reaction utilizing purified ribosomes, under the conditions described. (C–D) Western blot analysis of purified
biotin-conjugated puromycilated polypeptides, as indicated.
H3K9me2 + AUC H3K9me3), where AUC stands for Area
Under the Curve. This number was normalized by subtract-
ing the same percentage determined in the respective non-
enzymatic control. Pre-treatment of ribosomes were per-
formed sequentially as followed: incubation for 15 min at
80◦C, with 50 mM EDTA for 15 min at 37◦C.
In vitro labeling of translating nascent polypeptides
We labeled translating nascent polypeptides as described
(15). In brief, ribosomes (4 g of ribosomal RNA) were
incubated with or without 2 M of biotin-conjugated
puromycin (Jena Bioscience) in a buffer containing 10 mM
Tris (pH 7,4), 400 mM KCl and 3 mM MgCl2. After 90 min
at 37◦C the reaction was stopped by adding Laemmli Buffer.
For treatments, ribosomes were pre-incubated with either
0.1 g/l RNAse A or 50 mM EDTA for 15 min at 30◦C.
The reaction products were analyzed by Western blot us-
ing streptavidin-conjugated HRP (Abcam). For pull-down
assays, after labeling, the reaction was dialyzed against a
buffer containing 10 mM Tris (pH 7,4), 300 mM KCl and
3 mM MgCl2. Then, streptavidin conjugated agarose beads
(Thermo Scientific) were added, incubated for 90 min and
washed with the dialysis buffer containing 0.01% NP40. The
reaction products were analyzed by Western blot.
siRNA treatment
HeLa cells cultured at 80% confluence were transfected
with 30 nM of human SetDB1 siRNA duplex (SilencersPre-
designed, Ambion, Austin, TX, USA; ID: 138242, se-
quence: GGGCAGUGACUAAUUGUGAtt) using Lipo-
fectamine 2000 (Invitrogen), according to the manufac-
turer’s instructions. As a negative control, we used 30 nM
of negative control siRNA (Silencer Negative Control #1
siRNA, Ambion), a sequence designed without any signif-
icant similarity with mouse, rat or human transcripts se-
quences. 72 h post-transfection, cells were incubated with
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Figure 4. Ribosomes have a SetDB1-dependent H3K9 methyltransferase activity. (A) Increasing amounts of ribosomes (0.2 and 0.6 ug of RNA) were
analyzed by Western blot, as indicated. (B) Western blot analysis of samples derived from immunoprecipitation assays using 50 ug of ribosomal RNA
with antibodies against SetDB1 and RPS3a, as well as rabbit antibodies, as negative control. (C) Western blot of HeLa cell extracts treated with 30 nM of
either control or SetDB1 siRNA for 72 h, blotted as indicated. (D) Western blot of ribosomes purified by sucrose gradient from HeLa cells treated with
30 nM of either control or SetDB1 siRNA for 72 h, blotted as indicated. 50 ug of S100 cytosolic extract was loaded as a positive control. (E) Histone
methyltransferase assay using 3H-SAM, 5 M of histone H3 peptides from amino acids 1–20 that were either unmodified or trimethylated at the lysine 9,
and ribosomes purified by sucrose gradient from HeLa cells treated with 30 nM of either control or SetDB1 siRNA for 72 h. H3K9 methylation value was
obtained subtracting the cpms obtained in the reaction using H3(1–20)K9me3 peptide from the cpms obtained in the reaction containing the H3(1–20)
peptide. Standard deviation was obtained from triplicates.
0.1 mg/ml cycloheximide during 1 h and ribosomes were
purified as described (16). In brief, cells were lysed with the
S3 buffer (50 mM Hepes-KOH pH 7.4, 1 mM magnesium
acetate, 80 mM potassium acetate, 0.5% Triton X-100, 1
mM PMSF) during 15 min on ice, and centrifuged at 13
800 g for 15 min. The supernatant was loaded onto a 15%–
55% sucrose gradient in S3 buffer and ultracentrifuged in
the SW41 rotor (Beckman) for 4.5 h at 77 000 g, 4◦C. The
gradient was then fractioned in 300 l and each fraction an-
alyzed by 254 nm absorbance, Western blot for RPL5, and
agarose gel to detect the 28S and 18S rRNAs.
Filter H3 peptide methyltransferase assay
1 ug RNA of ribosomes derived from HeLa cells treated
with either control or SetDB1 siRNA were incubated with
1 ug of histone H3 peptide containing the first 20 amino
acids, in the presence of 3H-SAM for 20 min at 30◦C. The re-
action was stopped with acetic acid, spotted onto P81 filter
paper (Whatman), and washed with 50 mM Na2CO3. The
retained cpm was measured using a scintillation counter.
Immunoprecipitation assay
50 of polysomes RNA were incubated with either 1 g of
antibodies anti-SetDB1, anti-RPS3a or rabbit-IgG as neg-
ative control, in a buffer containing 10 mM Tris pH 7.4, 100
mM KCl, 3 mM MgCl2 and 0.01% NP40. After incubating
with protein A conjugated agarose beads, the beads were
washed five times with the incubation buffer. Western blot
analyses were performed with the immunoprecipitated sam-
ples.
Expression and purification of recombinant SetDB1
Flag-tagged recombinant human SetDB1 protein was ex-
pressed from baculovirus in SF9 cells and purified 72 h post-
infection by standard M2 affinity purification. After purifi-
cation the protein was eluted with 0.2 mg/ml of the Flag
peptide and dialyzed against a buffer containing 20 mM
Tris-HCl pH 7.9, 10% glycerol, 50 mM KCl, 0.2 mM EDTA,
10 mM B-mercaptoethanol, 0.2 mM PMSF.
RESULTS
Histone H3K9 mono- and dimethylation occurs at the ribo-
some
To investigate the timing of H3K9 methylation on newly
synthesized histone H3 polypeptides, we isolated and char-
acterized ribosome complexes translating histone H3. This
enables us to examine the earliest time point to assess
methylation. We enriched for elongating ribosomes by
preparing cell extracts from cycloheximide treated HeLa
cells and centrifuged them through a 35% sucrose cushion.
Western blot analysis of purified ribosomes reveal the pres-
ence of the large and small ribosomal subunits RPL5 and
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Figure 5. The ribosomal-associated H3K9 HMTase has a non-processive methylation mechanism. Progress curve of histone H3 peptide methylation using
unmodified histone H3 peptides from amino acids 1–20 and ribosome complexes (A) or recombinant SetDB1 (B). Each peptide, unmodified, mono-, di-
or trimethylated, was quantified and expressed as percent of the total H3 peptide. NE, non-enzymatic control. Standard deviation was obtained from three
independent assays. (C) Histone methyltransferase assay using unmodified histone H3 peptides from amino acids 1–20 and ribosome complexes. 75 min
after the reaction started, 10X molar excess of histone H3 full length protein was added to the reaction and allowed to proceed for additional 90 min. The
methylated peptides (H3K9me1 and H3K9me2) were quantified and expressed as percent of the total H3 peptides. H3K9 HMTase activity of the reaction
performed in the presence of competitor was expressed as percent of the reaction performed in the absence of competitor. Standard deviation was obtained
from three independent assays.
RPS3a proteins (Figure 1A), but not -actin, a cytosolic
protein that does not associate with ribosomes (Supplemen-
tary Figure S1A). Further characterization reveals 28S and
18S rRNAs on an agarose gel (Figure 1B). Importantly, we
confirm the presence of H3 in this ribosome complex (Fig-
ure 1A). Further supporting the specific interaction of H3
with mono-ribosomes, we find ribosomes co-eluting with a
second peak of histone H3, when centrifuged through a 15–
55% sucrose gradient (Supplementary Figure S2, fraction
18). We then used Western blot analysis to probe for the
presence of proteins that associate with soluble H3 com-
plexes (1,2). Consistent with previous results (17), we de-
tect the protein Hsc70 (Supplementary Figure S1A), a heat
shock protein that binds to nascent polypeptides to facili-
tate their correct folding. Importantly, we do not detect the
histone chaperones ASF1a/b and NASP, the cytoplasmic-
nuclear translocator protein Importin-4, nor the minichro-
mosome maintenance (MCM) proteins MCM2 and MCM5
(Supplementary Figure S1A). We also fail to detect the ded-
icated H3.1 chaperone CAF-1 (18), and two H3.3 chaper-
ones, Hir-related protein A (HIRA) and death associated
protein alpha (DAXX) (Supplementary Figure S1B) (3,18–
20). Taken together, our data suggest that the isolated ri-
bosome complexes are not contaminated with other solu-
ble chromatin assembly complexes and the associated H3
molecules most likely represent its recent translation.
We then investigated the methylation state of ribosome
bound H3 molecules. Interestingly, we detect significant
monomethylation of H3K9 (Figure 1A, left), but also
a fraction of dimethylated H3K9 (Figure 1A, middle).
Though we detect histone H4 associated with ribosomes,
we do not observe H4K12 acetylation (Figure 1A, right),
a hallmark of newly synthesized histones, consistent with
previous work showing that this mark occurs later in the
histone processing cascade (1,2). We then exploited mass
spectrometry approaches to assess other modifications. Im-
portantly, our analysis confirms that ribosome bound H3
features H3K9me1 and H3K9me2 (Figure 1C and Supple-
mentary Figure S3). Importantly, we do not detect methy-
lation on H3K4 or acetylation on H3K18 or H3K23 (Fig-
ure 1D), marks associated with nucleosomal histones. The
results support that ribosome-associated histones represent
a population of newly synthesized histones in early states
of the maturation cascade, rather than parental histones
evicted from nucleosomes. Taken together, our data demon-
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Figure 6. Working model: SetBD1 exists in two distinct complexes to establish H3K9 methylation to potentiate the final chromatin modification state. In
one complex, SetDB1 is bound to a population of ribosomes and methylates H3K9 during H3 polypeptide translation. This methylation would ensure that
a fraction of H3 features a particular pattern of modifications allowing the subsequent methylation by SUV39 to the H3K9me3 state. We propose that the
SetDB1/HP1/CAF-1 complex, which monomethylates H3K9 during heterochromatin replication, may also act as a contingency mechanism to ensure
sufficient H3K9 methylation enabling proper heterochromatin establishment and maintenance.
strate that H3K9 methylation occurs while H3 is associated
to ribosomes.
Ribosomes feature H3K9 mono- and dimethyltransferase ac-
tivity
We then asked whether our purified ribosome complexes
featured H3K9 methyltransferase activity. To address this
question we incubated the purified ribosome complexes
with H3 peptide substrates (aa 1–20), where H3K9 was un-
modified, mono-, di- or trimethylated, and analyzed the
methylation products by MALDI-TOF mass spectrometry.
We observe two product peaks shifted by 14 and 28 atomic
mass units (amu) with the unmodified substrate, consistent
with the addition of one and two methyl groups, respec-
tively, and one product peak shifted by 14 amu with the
H3K9me1 substrate. With the di- and trimethylated sub-
strates, we do not observe any product peaks (Figure 2A).
We then quantified the extent of methylation under our re-
action conditions and calculate 53% methylation of the un-
modified H3 peptide (including mono and dimethylation)
and 30% methylation of the H3K9me1 peptide (Figure 2B).
Notably, when incubating the ribosome complexes with the
histone peptides H3 (aa 21–34) and H4 (aa 1–21), we do not
observe any product peaks (Figure 2B and Supplementary
Figure S4). Together, these data demonstrate that ribosome
complexes feature a selective H3K9 mono- and dimethyl-
transferase activity.
Co-translational histone H3K9 methylation
We then assessed whether H3K9 methylation occurs dur-
ing H3 translation. We isolated elongating ribosomes from
cycloheximide treated HeLa cells and in vitro labeled trans-
lating polypeptides with Biotin-conjugated puromycin (Fig-
ure 3A), as previously described (15). We confirmed by
Western blot analysis that we only labeled newly syn-
thesized polypeptides upon addition of biotin-conjugated
puromycin (Figure 3B, lane 2). Further, when ribosomes
were pre-treated with either RNase or EDTA, nascent
polypeptides were not puromycilated (Figure 3B, lanes
4 and 6), confirming that active ribosomes are required
to label nascent polypeptides. We then purified biotin-
puromycin labeled nascent polypeptides with streptavidin-
coated beads and probed for H3 polypeptides. We re-
veal H3, indicating that at least a population of the ri-
bosomal bound histone H3 is in the process of transla-
tion (Figure 3C). Importantly, we also detect H3K9me1
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on purified nascent polypeptides (Figure 3D). Taken to-
gether, we conclude that methylation of H3K9 can occur
co-translationally.
Ribosomes have a SetDB1-dependent H3K9 methyltrans-
ferase activity
We previously showed that the methyltransferase SetDB1
catalyzes the monomethylation of H3K9 on soluble his-
tones (8), thus SetDB1 is an attractive candidate to methy-
late H3 associated to ribosomes. We first demonstrate that
SetDB1 associates to the ribosome complex using Western
blot analysis (Figure 4A) and co-immunoprecipitation ex-
periments (Figure 4B). We then asked whether this com-
plex featured SetDB1 catalytic activity. To address this, we
isolated ribosomes from HeLa cells treated with either a
control siRNA or siRNA targeting SetDB1 (siSetDB1).
We observe a 78% decrease in SetDB1 upon siRNA treat-
ment compared to control (Figure 4C). Importantly, siRNA
treatment does not affect the integrity of ribosomes, as
shown by the presence of the ribosomal protein RPL5 (Fig-
ure 4D). We then observe by Western blot analysis a de-
crease in H3K9me1 upon depletion of SetDB1 from ribo-
somes (Figure 4D). The residual H3K9me1 is likely due to
remaining SetDB1. We then assessed the ability of isolated
ribosomes depleted of SetDB1 to methylate H3 peptides.
Using a radioactive methyltransferase assay, we observed
a drastic decrease in methylation upon SetDB1 depletion
(Figure 4E). Together, the data suggest that SetDB1 asso-
ciates to ribosomes and methylates H3K9.
The ribosomal associated SetDB1 has a non-processive
methylation mechanism
Given that we observed H3K9me1 and H3K9me2 on
ribosomal-bound H3 molecules, we next assessed the mech-
anism that establishes these marks. Specifically, we asked
whether the catalytic activity is processive, where the en-
zyme remains bound to the substrate during subsequent
catalytic turnover (i.e. G9a (21)), or non-processive, where
the enzyme dissociates from the substrate after catalytic
turnover prior to catalyzing the second methyl transfer (i.e.
SUV39 (22)). We used MALDI-TOF MS to examine simul-
taneously the decrease in the starting unmethylated sub-
strate, the formation of the H3K9me1 intermediate, and
the formation of the H3K9me2 product. Under steady-state
conditions, if SetDB1 methylates the peptide in a processive
manner, we would not detect the H3K9me1 intermediate,
and the substrate depletion and product formation curves
would reciprocate each other. Conversely, if SetDB1 be-
haves in a non-processive manner, we should detect the ac-
cumulation of the H3K9me1 intermediate, and a lag phase
for the formation of the H3K9me2 final product. Indeed, we
observe a transient accumulation of the H3K9me1 peptide,
supporting the non-processive mechanism (Figure 5A). We
observe similar behavior using recombinant SetDB1, which
also trimethylates H3K9 (Figure 5B). Finally, we assessed
whether the addition of excess full-length H3 molecules af-
ter reaction initiation acted as a competitive inhibitor. In-
deed, we observe a decrease of the H3K9me2 product with
10-molar excess of full-length histone H3 (Figure 5C), fur-
ther supporting the non-processive mechanism. Taken to-
gether, our data demonstrate that SetDB1 associates to ri-
bosomes to establish the mono- and dimethylation mark on
H3K9 during translation in a non-processive manner.
DISCUSSION
Here, we report that mono- and dimethylation of H3K9 oc-
curs while H3 is associated to ribosomes (Figure 1) and that
the reaction is catalyzed during H3 translation (Figure 3)
by the SetDB1 methyltransferase (Figure 4). This is, to the
best of our knowledge, the first histone modification shown
to occur during translation, supporting the critical nature
of this mark for genome integrity.
SetDB1 establishes the H3K9 methylation mark on ribo-
somes by a non-processive mechanism
We show that ribosomal-associated SetDB1 acts via a non-
processive mechanism to catalyze H3K9me1 and H3K9me2
(Figure 5). Interestingly, with the exception of SUV39
(22,23), most H3K9 methyltransferases, including G9a (21)
and the neurospora DIM-5 (24), utilize a processive mech-
anism to methylate their substrates. We hypothesize that
the non-processive methylation mechanism enables a level
of regulation toward the extent of methylation on ribo-
somes. Further work should investigate whether the speed
of mRNA translation might bias methylation toward ei-
ther mono or dimethylation. For example, if H3 polypeptide
synthesis and/or protein folding is fast, potentially during
S-phase, the formation of H3K9me1 would be favored over
H3K9me2. Given that recombinant SetDB1 can trimethy-
late H3K9 (Figure 5), it would also be interesting to con-
sider that under stress conditions trimethylation may be
possible if there is a delay in histone translation. This could
potentially bypass the need for SUV39 to expedite hete-
rochromatin formation or alternatively may act as a signal
for defective histones that need to be degraded.
Two mechanisms to establish newly synthesized H3K9 methy-
lation
It is interesting to consider that SetDB1 acts by two distinct
mechanisms to methylate H3K9 (Figure 6). The first mech-
anism, reported here, establishes H3K9me1/2 during trans-
lation. This creates an immediate pool of newly synthesized
histones that once deposited onto DNA serve as a tem-
plate for additional modifications that will give rise to het-
erochromatin domains. Of course, one cannot rule out that
newly synthesized H3K9 methylation might play other roles
as well, including histone folding, the regulation of protein–
protein interactions or histone degradation. Secondly, we
previously reported a SetDB1/HP1/CAF-1 complex that
monomethylates soluble H3K9 as a mechanism to ensure
heterochromatin maintenance after replication or DNA
damage repair (8). This complex may operate through two
distinct mechanisms: (i) to handle parental histones evicted
from chromatin, using SetDB1 to methylate H3K9, prior
to recycling the parental histones onto newly synthesized
DNA, and (ii) as a contingency plan in case there are errors
in the metabolism of newly synthesized histones. Future
Nucleic Acids Research, 2015, Vol. 43, No. 19 9105
work should consider how the balance of SetDB1 in those
two complexes shifts through the cell cycle and the resulting
functional implications such as heterochromatin integrity.
Interestingly, SetDB1 is overexpressed in several cancers in-
cluding human melanomas (25), and the SetDB1 gene is
amplification in some lung tumors (26,27). The change in
the dosage of SetDB1 could further impact the balance of
the SetDB1 protein in the two complexes and lead to aber-
rant or perturbed heterochromatin domains. Furthermore,
SetDB1 depletion using RNAi approaches in cancer cell
lines or mouse xenograft models leads to a decrease in pro-
liferation (27). Therefore, SetDB1 could represent a new
therapeutic target in tumors overexpressing SetDB1 or with
heterochromatin defects. Taken together, our work charac-
terized for the first time a mechanism to establish histone
methylation during translation, and highlights the impor-
tance of considering histone dynamics outside of chromatin
as critical contributors to genome integrity.
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